Search

Siponimod

[L5801] MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792] … It was approved by the FDA on March 26, 2019 [L5792] and by Health Canada on February 20, 2020.

Ephedra sinica root

The drug is still sold in Canada in OTC formulations for respiratory conditions associated with bronchial asthma. … The sale of ephedra-containing supplements intended to increase muscle weight or promote weight loss was banned in the United States in 2004 due to the risk for adverse effects and a lack of evidence for

Procaine

(From Martindale, The Extra Pharmacopoeia, 30th ed, p1016). Procaine has also been investigated as an oral entry inhibitor in treatment-experienced HIV patients [L1215].

Fluciclovine (18F)

It presents excellent diagnostic properties to be used in positron emission tomography (PET) imaging. … [A31385] Fluciclovine was developed by Blue Earth Diagnostics, Ltd. and FDA approved in May 27, 2016.[L1049]

Bifidobacterium longum infantis

Urea C-13

Radiolabelled urea is available in two forms as 13C and 14C. … As the urease enzyme is not present in mammalian cells, the presence of urease (and the products of urea cleavage) in the stomach is evidence that H. pylori bacteria are present.

Lurasidone

Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. … Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S.

Ferric maltol

[A189291] Ferric maltol was initially granted FDA approval on July 25, 2019, for use in adults. … Ferric maltol is an iron(III) atom complexed with 3 maltol molecules to increase the bioavailability compared to iron(II), without depositing it in the duodenum as insoluble ferric hydroxide and phosphate

Golimumab

Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate … treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe

Rescinnamine

Rescinnamine is an angiotensin-converting enzyme inhibitor used as an antihypertensive drug. It is an alkaloid obtained from _Rauwolfia serpentina_ and other species of _Rauwolfia_.